Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses

Kung-Chao Chang, Guan Cheng Huang, Dan Jones, Ya Hui Lin

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphomas, accounts for 30% to 40% of all lymphoma cases. However, long-term survival by current chemotherapy was achieved in only 40% of patients, warranting the development of novel therapeutic strategies including T-cell immunotherapy. However, the level of baseline immune activation in DLBCL is unclear. Experimental Design: The density and distribution of dendritic cells and T cells in 48 cases of primary DLBCL was evaluated by immunohistochemistry. Results: Increased numbers of intratumoral CD1a+ dendritic cells and increased S100+ cells and CD45RO+ T cells around the edges of the tumors were seen in 10 of 48 (21%), 9 of 48 (19%), and 10 of 48 (21%) cases and these were correlated with a favorable prognosis (P = 0.015; P = 0.070, and P = 0.017, respectively), along with increased granzyme B + T cells in tumor beds (P = 0.013). Increased peritumoral T cells were correlated with tumor expression of HLA-DR (r = 0.446; P = 0.002). Extranodal lymphomas showed fewer tumor-associated CD45RO+ T cells (r =-0.407; P = 0.001) and less conspicuous dendritic cell infiltrates. Conclusions: In DLBCL, the presence of baseline antitumor immune response is associated with favorable clinical outcome, and thus adjuvant T-cell immunotherapy may further boost treatment responses.

Original languageEnglish
Pages (from-to)6666-6672
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number22
DOIs
Publication statusPublished - 2007 Nov 15

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Dendritic Cells
T-Lymphocytes
Immunotherapy
Lymphoma
Neoplasms
Granzymes
HLA-DR Antigens
Non-Hodgkin's Lymphoma
Research Design
Immunohistochemistry
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{9a36fb51fc69423db518424709cd6dff,
title = "Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses",
abstract = "Purpose: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphomas, accounts for 30{\%} to 40{\%} of all lymphoma cases. However, long-term survival by current chemotherapy was achieved in only 40{\%} of patients, warranting the development of novel therapeutic strategies including T-cell immunotherapy. However, the level of baseline immune activation in DLBCL is unclear. Experimental Design: The density and distribution of dendritic cells and T cells in 48 cases of primary DLBCL was evaluated by immunohistochemistry. Results: Increased numbers of intratumoral CD1a+ dendritic cells and increased S100+ cells and CD45RO+ T cells around the edges of the tumors were seen in 10 of 48 (21{\%}), 9 of 48 (19{\%}), and 10 of 48 (21{\%}) cases and these were correlated with a favorable prognosis (P = 0.015; P = 0.070, and P = 0.017, respectively), along with increased granzyme B + T cells in tumor beds (P = 0.013). Increased peritumoral T cells were correlated with tumor expression of HLA-DR (r = 0.446; P = 0.002). Extranodal lymphomas showed fewer tumor-associated CD45RO+ T cells (r =-0.407; P = 0.001) and less conspicuous dendritic cell infiltrates. Conclusions: In DLBCL, the presence of baseline antitumor immune response is associated with favorable clinical outcome, and thus adjuvant T-cell immunotherapy may further boost treatment responses.",
author = "Kung-Chao Chang and Huang, {Guan Cheng} and Dan Jones and Lin, {Ya Hui}",
year = "2007",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-07-0504",
language = "English",
volume = "13",
pages = "6666--6672",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. / Chang, Kung-Chao; Huang, Guan Cheng; Jones, Dan; Lin, Ya Hui.

In: Clinical Cancer Research, Vol. 13, No. 22, 15.11.2007, p. 6666-6672.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses

AU - Chang, Kung-Chao

AU - Huang, Guan Cheng

AU - Jones, Dan

AU - Lin, Ya Hui

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Purpose: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphomas, accounts for 30% to 40% of all lymphoma cases. However, long-term survival by current chemotherapy was achieved in only 40% of patients, warranting the development of novel therapeutic strategies including T-cell immunotherapy. However, the level of baseline immune activation in DLBCL is unclear. Experimental Design: The density and distribution of dendritic cells and T cells in 48 cases of primary DLBCL was evaluated by immunohistochemistry. Results: Increased numbers of intratumoral CD1a+ dendritic cells and increased S100+ cells and CD45RO+ T cells around the edges of the tumors were seen in 10 of 48 (21%), 9 of 48 (19%), and 10 of 48 (21%) cases and these were correlated with a favorable prognosis (P = 0.015; P = 0.070, and P = 0.017, respectively), along with increased granzyme B + T cells in tumor beds (P = 0.013). Increased peritumoral T cells were correlated with tumor expression of HLA-DR (r = 0.446; P = 0.002). Extranodal lymphomas showed fewer tumor-associated CD45RO+ T cells (r =-0.407; P = 0.001) and less conspicuous dendritic cell infiltrates. Conclusions: In DLBCL, the presence of baseline antitumor immune response is associated with favorable clinical outcome, and thus adjuvant T-cell immunotherapy may further boost treatment responses.

AB - Purpose: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphomas, accounts for 30% to 40% of all lymphoma cases. However, long-term survival by current chemotherapy was achieved in only 40% of patients, warranting the development of novel therapeutic strategies including T-cell immunotherapy. However, the level of baseline immune activation in DLBCL is unclear. Experimental Design: The density and distribution of dendritic cells and T cells in 48 cases of primary DLBCL was evaluated by immunohistochemistry. Results: Increased numbers of intratumoral CD1a+ dendritic cells and increased S100+ cells and CD45RO+ T cells around the edges of the tumors were seen in 10 of 48 (21%), 9 of 48 (19%), and 10 of 48 (21%) cases and these were correlated with a favorable prognosis (P = 0.015; P = 0.070, and P = 0.017, respectively), along with increased granzyme B + T cells in tumor beds (P = 0.013). Increased peritumoral T cells were correlated with tumor expression of HLA-DR (r = 0.446; P = 0.002). Extranodal lymphomas showed fewer tumor-associated CD45RO+ T cells (r =-0.407; P = 0.001) and less conspicuous dendritic cell infiltrates. Conclusions: In DLBCL, the presence of baseline antitumor immune response is associated with favorable clinical outcome, and thus adjuvant T-cell immunotherapy may further boost treatment responses.

UR - http://www.scopus.com/inward/record.url?scp=36749013021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749013021&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0504

DO - 10.1158/1078-0432.CCR-07-0504

M3 - Article

VL - 13

SP - 6666

EP - 6672

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -